Nanoscope Therapeutics Announces Presentations at The Retina Society 56th Annual Scientific Meeting
DALLAS, Oct. 9, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and macular degenerations, today announced presentations at The Retina Society 56th Annual Scientific Meeting taking place in New York, New York from October 11-14, 2023.
Details for the presentations are as follows:
Title: MCO-010 Optogenetic Vision Restoration in Retinitis Pigmentosa Patients with Profound Vision Loss: A Randomized, Sham-Controlled, Multi-center, Double-Masked Clinical Trial (RESTORE)
Session Title: Genetic Diseases, Dystrophies & Degenerations
In her presentation, Dr. Kay will discuss clinical data and analysis from Nanoscope's Phase 2b RESTORE trial in patients with advanced retinitis pigmentosa.
Title: MCO-010 Optogenetic Therapy for Profound Vision Loss in Stargardt Disease: 12-Month Outcomes from the Phase 2 STARLIGHT Trial
Session Title: Imaging
In this late-breaking presentation, Dr. Ho will discuss recent 1 year data from Nanoscope's Phase 2 STARLIGHT trial of MCO-010 therapy in patients with advanced Stargardt macular degeneration.
About Nanoscope Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentations-at-the-retina-society-56th-annual-scientific-meeting-301950250.html
SOURCE Nanoscope Therapeutics